Prometic announces closing of $60 million bought deal offering of common shares

May 25, 2016 Fred Dumais

LAVAL, QUEBEC, CANADA – May 25, 2016 – ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF)(“ProMetic” or the “Corporation”) closed today its previously announced bought deal public offering of common shares in the capital of the Corporation (the “Offering”) through a syndicate of underwriters led by RBC Capital Markets and Canaccord Genuity Corp., and which included Scotiabank, CIBC Capital Markets, National Bank Financial Inc., Paradigm Capital Inc. and Beacon Securities Limited (collectively, the “Underwriters”). ProMetic issued 19,400,000 common shares of the Corporation in connection with the Offering at a price of $3.10 per share for aggregate gross proceeds of $60,140,000. In consideration for the services rendered by the Underwriters under the Offering, the Underwriters received a cash commission representing 5% of the gross proceeds of the Offering.

As previously disclosed, the Corporation intends to use the net proceeds from the Offering for: (1) the advancement of clinical programs relating to the Corporation’s orally active anti-fibrotic drug PBI-4050, such as scleroderma and cystic fibrosis, (2) the scale-up of PBI-4050 follow-on drug candidates and their advancement into clinical stages, (3) the advancement of new clinical indications for Plasminogen, including wound healing, (4) the expansion of clinical uses and proprietary positions on some plasma-derived orphan drugs, and (5) the expansion of manufacturing capabilities related to the plasma-derived therapeutics. These initiatives, as well as providing additional working capital, will allow the Corporation to continue to exercise greater control and ownership over its technology platforms, thereby providing an opportunity to retain a greater portion of the associated value for its shareholders.

The Corporation also announced today that it has closed its previously disclosed concurrent private placement entered into with Structured Alpha LP (“SALP”), an affiliate of Thomvest Asset Management Inc. This concurrent private placement was entered into following the exercise by SALP of its pre-emptive right to participate in any future public offering of ProMetic’s common shares. The private placement is for the subscription of 1,921,776 common shares of the Corporation at a price of $3.10 per common share, which will be satisfied by the cancellation of indebtedness owing to SALP by ProMetic.

About ProMetic Life Sciences Inc.

ProMetic Life Sciences Inc. ( is a long established biopharmaceutical company with globally recognized expertise in bioseparations, plasma-derived therapeutics and small-molecule drug development. ProMetic offers its state of the art technologies for large-scale purification of biologics, drug development, proteomics and the elimination of pathogens to a growing base of industry leaders and uses its own affinity technology that provides for highly efficient extraction and purification of therapeutic proteins from human plasma in order to develop best-in-class therapeutics and orphan drugs. ProMetic is also active in developing its own novel small-molecule therapeutic products targeting unmet medical needs in the field of fibrosis, anemia, neutropenia, cancer and autoimmune diseases/inflammation as well as certain nephropathies. Headquartered in Laval (Canada), ProMetic has R&D facilities in the UK, the U.S. and Canada, manufacturing facilities in the UK and commercial activities in the U.S., Canada, Europe, Russia, Australia and Asia.

Forward Looking Statements

This press release contains forward-looking statements about ProMetic’s objectives, strategies and businesses, including statements regarding how the Corporation intends to use the net proceeds from the Offering, that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, ProMetic’s ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of ProMetic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in ProMetic’s Annual Information Form for the year ended December 31, 2015, under the heading “Risks and Uncertainties related to ProMetic’s Business”. As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations. All amounts are in Canadian dollars unless indicated otherwise.

About the Author

Fred Dumais

Fred is responsible for leading Prometic’s investor relations team and is accountable for all global investor relations activity, PR and event management. He joined the company in 2001, and brings nearly twenty years of experience in investor and financial communications, as well as a deep experience of the pharmaceutical industry. He has extensive knowledge of the global financial markets in the US, Europe and his native country of Canada. Fred is a graduate from Concordia University where he gained a BA in Business Communications. He also brings to the role a background in law with a LLB from the University of Québec.

Previous Article
Prometic to present new data on how PBI-4050 keeps pancreatic beta cells alive at the American Diabetic Association’s upcoming meeting
Prometic to present new data on how PBI-4050 keeps pancreatic beta cells alive at the American Diabetic Association’s upcoming meeting

PBI-4050’s unique mechanism of action shown to keep insulin-producing pancreatic beta cells alive and trans...

Next Article
Health Canada authorizes Prometic to proceed with its PBI-4050 clinical trial in patients with Cystic Fibrosis
Health Canada authorizes Prometic to proceed with its PBI-4050 clinical trial in patients with Cystic Fibrosis

ProMetic approved to commence the clinical trial of its orally active anti-fibrotic lead drug candidate, PB...